SS Innovations International, Inc. (NASDAQ: SSII) has announced significant growth in the utilization and global reach of its SSi Mantra surgical robotic system. As of September 8, 2026, the company reported 14,103 cumulative procedures performed using the SSi Mantra, a 79% increase from 7,885 procedures at the end of 2025. The installed base of systems grew 42% to 238 units, up from 168 at year-end 2025. These figures underscore the accelerating adoption of the SSi Mantra platform in hospitals worldwide.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system. It has been used for more than 170 types of surgical procedures, demonstrating its versatility across a wide range of surgical specialties. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's success in penetrating new markets and expanding the clinical applications of its technology.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a record-setting telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability in high-volume settings. Such achievements are critical as they demonstrate the platform's capability to support complex, remote surgical interventions and high-throughput surgical programs.
Looking ahead, the company expects the U.S. Food and Drug Administration (FDA) to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal for the company's expansion into two of the largest and most lucrative medical device markets. Successful clearance would enable SS Innovations to compete directly with established players in the global surgical robotics market, potentially driving further growth in procedures and installations.
The implications of these announcements are substantial. The rapid increase in procedures and installed base indicates strong market acceptance and trust in the SSi Mantra system. The expansion into new countries and the achievement of telesurgery milestones position SS Innovations as a leader in making robotic surgery more accessible and affordable. The company's focus on cost-effective solutions could disrupt the market by offering a viable alternative to more expensive systems, thereby broadening access to advanced surgical care in both developed and emerging markets.
For investors, the pending FDA and CE mark approvals represent key catalysts that could significantly enhance the company's revenue potential and market valuation. The growing body of clinical evidence and the expanding global footprint provide a solid foundation for future growth. As SS Innovations continues to train physicians and add new surgical capabilities, its impact on the global surgical robotics landscape is likely to intensify.
To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
